SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Young-Hoon Sung, Deborah A. Yurgelun-Todd, Douglas G. Kondo, Xian-Feng Shi, Kelly J. Lundberg, Tracy L. Hellem, Rebekah S. Huber, Erin C. McGlade, Eun-Kee Jeong, Perry F. Renshaw, Gender differences in the effect of tobacco use on brain phosphocreatine levels in methamphetamine-dependent subjects, The American Journal of Drug and Alcohol Abuse, 2015, 1

    CrossRef

  2. 2
    Philippe Huot, Susan H. Fox, Jonathan M. Brotchie, Monoamine Reuptake Inhibitors in Parkinson’s Disease, Parkinson's Disease, 2015, 2015, 1

    CrossRef

  3. 3
    Shaobin Yu, Ling Zhu, Qiang Shen, Xue Bai, Xuhui Di, Recent Advances in Methamphetamine Neurotoxicity Mechanisms and Its Molecular Pathophysiology, Behavioural Neurology, 2015, 2015, 1

    CrossRef

  4. 4
    J. Sanchez-Ramos, 2015,

    CrossRef

  5. 5
    Anna Durbin, David Rudoler, Janet Durbin, Audrey Laporte, Russell C. Callaghan, Examining Patient Race and Area Predictors of Inpatient Admission for Schizophrenia Among Hospital Users in California, Journal of Immigrant and Minority Health, 2014, 16, 6, 1025

    CrossRef

  6. 6
    Eun-Joo Shin, Seung Woo Shin, Thuy-Ty Lan Nguyen, Dae Hun Park, Myung-Bok Wie, Choon-Gon Jang, Seung-Yeol Nah, Byung Wook Yang, Sung Kwon Ko, Toshitaka Nabeshima, Hyoung-Chun Kim, Ginsenoside Re Rescues Methamphetamine-Induced Oxidative Damage, Mitochondrial Dysfunction, Microglial Activation, and Dopaminergic Degeneration by Inhibiting the Protein Kinase Cδ Gene, Molecular Neurobiology, 2014, 49, 3, 1400

    CrossRef

  7. 7
    Danielle M. Friend, Ashley N. Fricks-Gleason, Kristen A. Keefe, Is There a Role for Nitric Oxide in Methamphetamine-Induced Dopamine Terminal Degeneration?, Neurotoxicity Research, 2014, 25, 2, 153

    CrossRef

  8. 8
    Giulia Costa, Nicola Simola, Micaela Morelli, MDMA administration during adolescence exacerbates MPTP-induced cognitive impairment and neuroinflammation in the hippocampus and prefrontal cortex, Psychopharmacology, 2014, 231, 20, 4007

    CrossRef

  9. 9
    Laura E. Halpin, Stuart A. Collins, Bryan K. Yamamoto, Neurotoxicity of methamphetamine and 3,4-methylenedioxymethamphetamine, Life Sciences, 2014, 97, 1, 37

    CrossRef

  10. 10
    Matthew J. Robson, Ryan C. Turner, Zachary J. Naser, Christopher R. McCurdy, James P. O'Callaghan, Jason D. Huber, Rae R. Matsumoto, SN79, a sigma receptor antagonist, attenuates methamphetamine-induced astrogliosis through a blockade of OSMR/gp130 signaling and STAT3 phosphorylation, Experimental Neurology, 2014, 254, 180

    CrossRef

  11. 11
    Omid Tavassoly, Joe Kakish, Sergiy Nokhrin, Oleg Dmitriev, Jeremy S. Lee, The use of nanopore analysis for discovering drugs which bind to α-synuclein for treatment of Parkinson's disease, European Journal of Medicinal Chemistry, 2014, 88, 42

    CrossRef

  12. 12
    Danielle M. Friend, Kristen A. Keefe, A role for D1 dopamine receptors in striatal methamphetamine-induced neurotoxicity, Neuroscience Letters, 2013, 555, 243

    CrossRef

  13. 13
    Anna-Karin Eriksson, Sofia Löfving, Russell C Callaghan, Peter Allebeck, Alcohol use disorders and risk of Parkinson’s disease: findings from a Swedish national cohort study 1972–2008, BMC Neurology, 2013, 13, 1, 190

    CrossRef

  14. 14
    Ashley N. Fricks-Gleason, Kristen A. Keefe, Evaluating the Role of Neuronal Nitric Oxide Synthase-Containing Striatal Interneurons in Methamphetamine-Induced Dopamine Neurotoxicity, Neurotoxicity Research, 2013, 24, 2, 288

    CrossRef

  15. 15
    Danielle M. Friend, Kristen A. Keefe, Glial reactivity in resistance to methamphetamine-induced neurotoxicity, Journal of Neurochemistry, 2013, 125, 4
  16. 16
    Noelia Granado, Sara Ares-Santos, Rosario Moratalla, Methamphetamine and Parkinson's Disease, Parkinson's Disease, 2013, 2013, 1

    CrossRef

  17. 17
    William J. Panenka, Ric M. Procyshyn, Tania Lecomte, G. William MacEwan, Sean W. Flynn, William G. Honer, Alasdair M. Barr, Methamphetamine use: A comprehensive review of molecular, preclinical and clinical findings, Drug and Alcohol Dependence, 2013, 129, 3, 167

    CrossRef

  18. 18
    Giulia Costa, Lucia Frau, Jadwiga Wardas, Annalisa Pinna, Antonio Plumitallo, Micaela Morelli, MPTP-induced dopamine neuron degeneration and glia activation is potentiated in MDMA-pretreated mice, Movement Disorders, 2013, 28, 14
  19. 19
    Daniel E. Rusyniak, Neurologic Manifestations of Chronic Methamphetamine Abuse, Psychiatric Clinics of North America, 2013, 36, 2, 261

    CrossRef

  20. 20
    Bin Liu, Roberta Traini, Bryan Killinger, Bernard Schneider, Anna Moszczynska, Overexpression of parkin in the rat nigrostriatal dopamine system protects against methamphetamine neurotoxicity, Experimental Neurology, 2013, 247, 359

    CrossRef

  21. 21
    Matthew J. Robson, Ryan C. Turner, Zachary J. Naser, Christopher R. McCurdy, Jason D. Huber, Rae R. Matsumoto, SN79, a sigma receptor ligand, blocks methamphetamine-induced microglial activation and cytokine upregulation, Experimental Neurology, 2013, 247, 134

    CrossRef

  22. 22
    Michael J. Seminerio, Rolf Hansen, Nidhi Kaushal, Han-Ting Zhang, Christopher R. McCurdy, Rae R. Matsumoto, The evaluation of AZ66, an optimized sigma receptor antagonist, against methamphetamine-induced dopaminergic neurotoxicity and memory impairment in mice, The International Journal of Neuropsychopharmacology, 2013, 16, 05, 1033

    CrossRef

  23. 23
    J L Oei, A Kingsbury, A Dhawan, L Burns, J M Feller, S Clews, J Falconer, M E Abdel-Latif, Amphetamines, the pregnant woman and her children: a review, Journal of Perinatology, 2012, 32, 10, 737

    CrossRef

  24. 24
    Chadwick W. Christine, William J. Marks, Jill L. Ostrem, Development of Parkinson’s disease in patients with Narcolepsy, Journal of Neural Transmission, 2012, 119, 6, 697

    CrossRef

  25. 25
    Anumantha Kanthasamy, Huajun Jin, Vellareddy Anantharam, Gautam Sondarva, Velusamy Rangasamy, Ajay Rana, Arthi Kanthasamy, Emerging neurotoxic mechanisms in environmental factors-induced neurodegeneration, NeuroToxicology, 2012, 33, 4, 833

    CrossRef

  26. 26
    Russell C. Callaghan, James K. Cunningham, Jenna Sykes, Stephen J. Kish, Increased risk of Parkinson's disease in individuals hospitalized with conditions related to the use of methamphetamine or other amphetamine-type drugs, Drug and Alcohol Dependence, 2012, 120, 1-3, 35

    CrossRef

  27. 27
    Wolfgang H. Jost, Michael Friede, Jörg Schnitker, Indirect meta-analysis of randomised placebo-controlled clinical trials on rasagiline and selegiline in the symptomatic treatment of Parkinson’s disease, Basal Ganglia, 2012, 2, 4, S17

    CrossRef

  28. 28
    Omid Tavassoly, Jeremy S. Lee, Methamphetamine binds to α-synuclein and causes a conformational change which can be detected by nanopore analysis, FEBS Letters, 2012, 586, 19, 3222

    CrossRef

  29. 29
    John R. Sladek, Neural development, a risky period, Experimental Neurology, 2012, 237, 1, 43

    CrossRef

  30. 30
    Mélanie Bourque, Dean E. Dluzen, Thérèse Di Paolo, Sex and temporally-dependent effects of methamphetamine toxicity on dopamine markers and signaling pathways, Neuropharmacology, 2012, 62, 7, 2363

    CrossRef

  31. 31
    B.A. Morrow, R.H. Roth, D.E. Redmond, S. Diano, J.D. Elsworth, Susceptibility to a parkinsonian toxin varies during primate development, Experimental Neurology, 2012, 235, 1, 273

    CrossRef

  32. 32
    Courtney M. Keller, Michael F. Salvatore, Brandon S. Pruett, Glenn F. Guerin, Nicholas E. Goeders, Biphasic dopamine regulation in mesoaccumbens pathway in response to non-contingent binge and escalating methamphetamine regimens in the Wistar rat, Psychopharmacology, 2011, 215, 3, 513

    CrossRef

  33. 33
    B.A. Morrow, R.H. Roth, D.E. Redmond, J.D. Elsworth, Impact of methamphetamine on dopamine neurons in primates is dependent on age: implications for development of Parkinson's disease, Neuroscience, 2011, 189, 277

    CrossRef

  34. 34
    Sharanya M. Kousik, Steven M. Graves, T. Celeste Napier, Chaohui Zhao, Paul M. Carvey, Methamphetamine-induced vascular changes lead to striatal hypoxia and dopamine reduction, NeuroReport, 2011, 22, 17, 923

    CrossRef

  35. 35
    P W Kalivas, N D Volkow, New medications for drug addiction hiding in glutamatergic neuroplasticity, Molecular Psychiatry, 2011, 16, 10, 974

    CrossRef